ChartRow logo
EXEL
Exelixis Inc.Stock · Health Care
$52.20−$4.50 (-7.94%)as of market close, Aug 6, 2026
CompareLLYUNHJNJABBVISRGTMO

EXEL financial statements

The full income statement, balance sheet, and cash-flow statement for Exelixis Inc. (EXEL), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Shares outstanding (point-in-time)

2024-06 285.3M2024-09 285.6M2025-01 279.9M2025-04 272.7M2025-07 269.2M2025-10 268.1M2026-01 259.7M2026-04 251.4M2026-07 247.8M-13.1% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

As-reported fiscal years.
Line itemTrendFY2025FY2024FY2023FY2022FY2021
Income Statementas ofJan 2 ’26as ofJan 3 ’25as ofDec 29 ’23as ofDec 30 ’22as ofDec 31 ’21
Revenue
2.32B
YoY+7.0%
2.17B
YoY+18.5%
1.83B
YoY+13.6%
1.61B
YoY+12.3%
1.43B
YoY+45.3%
Cost of revenue
83.7M
YoY+9.8%
76.2M
YoY+5.1%
72.5M
YoY+25.3%
57.9M
YoY+9.5%
52.9M
YoY+45.8%
Research & development
825M
YoY-9.4%
910M
YoY-12.8%
1.04B
YoY+17.1%
892M
YoY+28.6%
694M
YoY+26.6%
Selling, general & administrative
519M
YoY+5.4%
492M
YoY-9.3%
543M
YoY+18.0%
460M
YoY+14.5%
402M
YoY+36.9%
Restructuring
20.5M
YoY-39.1%
33.7M
0.00
0.00
Operating income
872M
YoY+44.3%
605M
YoY+253.8%
171M
YoY-15.2%
201M
YoY-29.7%
287M
YoY+160.5%
Other non-operating income
-198K
YoY-48.9%
-133K
YoY-243.0%
93.0K
YoY+147.2%
-197K
YoY-7.1%
-184K
YoY-120.2%
Income tax
159M
YoY-1.1%
160M
YoY+222.3%
49.8M
YoY-4.4%
52.1M
YoY-17.5%
63.1M
YoY+231.1%
Net income
783M
YoY+50.1%
521M
YoY+150.9%
208M
YoY+14.0%
182M
YoY-21.1%
231M
YoY+106.7%
$2.78
YoY+58.0%
$1.76
YoY+170.8%
$0.65
YoY+16.1%
$0.56
YoY-22.2%
$0.72
YoY+105.7%
Balance Sheetas ofJan 2 ’26as ofJan 3 ’25as ofDec 29 ’23as ofDec 30 ’22as ofDec 31 ’21
1.44B
YoY-1.7%
1.47B
YoY+11.4%
1.32B
YoY-18.6%
1.62B
YoY-11.8%
1.83B
YoY+26.9%
2.84B
YoY-3.5%
2.95B
YoY+0.2%
2.94B
YoY-4.2%
3.07B
YoY+17.4%
2.62B
YoY+22.4%
406M
YoY+0.5%
404M
YoY+2.4%
394M
YoY+21.6%
324M
YoY-3.9%
338M
YoY+65.0%
683M
YoY-2.9%
703M
YoY+3.7%
678M
YoY+16.4%
583M
YoY+43.7%
406M
YoY+57.1%
2.16B
YoY-3.7%
2.24B
YoY-0.9%
2.26B
YoY-9.0%
2.49B
YoY+12.6%
2.21B
YoY+17.6%
Cash Flowas ofJan 2 ’26as ofJan 3 ’25as ofDec 29 ’23as ofDec 30 ’22as ofDec 31 ’21
884M
YoY+26.3%
700M
YoY+110.0%
333M
YoY-8.1%
363M
YoY-9.5%
401M
YoY+91.8%
350M
YoY+400.1%
-117M
YoY-333.3%
-27.0M
YoY+94.9%
-524M
YoY-1122.9%
-42.9M
YoY+67.3%
-970M
YoY-54.2%
-629M
YoY-15.2%
-546M
YoY-93282.9%
586K
YoY+104.0%
-14.8M
YoY+41.1%
Net change in cash
265M
YoY+681.1%
-45.6M
YoY+81.0%
-240M
YoY-48.7%
-161M
YoY-147.0%
343M
YoY+551.9%
Income taxes paid
155M
YoY-8.9%
170M
YoY-8.2%
186M
YoY+45.2%
128M
YoY+886.7%
13.0M
YoY+214.9%
Valuation Ratiosas ofJan 2 ’26as ofJan 3 ’25as ofDec 29 ’23as ofDec 30 ’22as ofDec 31 ’21
Market cap
11.3B
YoY+19.0%
9.51B
YoY+30.7%
7.27B
YoY+39.9%
5.20B
YoY-11.0%
5.84B
YoY-6.2%
P/E
14.5×
YoY-20.7%
18.2×
YoY-47.9%
35.0×
YoY+22.8%
28.5×
YoY+12.8%
25.3×
YoY-38.3%
P/S
4.9×
YoY+11.3%
4.4×
YoY+10.3%
4.0×
YoY+23.2%
3.2×
YoY-20.7%
4.1×
YoY-37.4%
P/B
5.2×
YoY+23.6%
4.2×
YoY+31.9%
3.2×
YoY+53.8%
2.1×
YoY-20.9%
2.6×
YoY-21.4%
P/FCF
12.9×
YoY-8.7%
14.2×
YoY-43.0%
24.8×
YoY+60.0%
15.5×
YoY-7.9%
16.8×
YoY-16.0%
6.9%
YoY+26.1%
5.5%
YoY+91.9%
2.9%
YoY-18.5%
3.5%
YoY-11.4%
4.0%
YoY+61.9%
7.7%
YoY+9.6%
7.1%
YoY+75.4%
4.0%
YoY-37.5%
6.4%
YoY+8.6%
5.9%
YoY+19.1%
Source filing10-K10-K10-K10-K10-K

About this data

Source: EXEL's SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn't file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all EXEL filings on SEC EDGAR → Not investment advice.